Economic evaluation for the United States (US) of gemcitabine (GEM), nab-paclitaxel plus gemcitabine (NAB-P plus GEM), and FOLFIRINOX as first-line treatment for metastatic pancreatic cancer (MPC)

被引：0
|
作者：
Gharaibeh, Mahdi
McBride, Ali
Bootman, J. Lyle
Cranmer, Lee D.
Abraham, Ivo
机构：
[1] Ctr Hlth Outcomes & PharmacoEcon Res, Tucson, AZ USA
[2] Univ Arizona, Ctr Canc, Tucson, AZ USA
[3] Univ Arizona, Ctr Hlth Outcomes & PharmacoEcon Res, Tucson, AZ USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 15期
关键词：
D O I：
10.1200/jco.2015.33.15_suppl.6605
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
6605
引用
收藏
页数：1
相关论文
共 50 条
  • [31] FOLFIRINOX or nab-paclitaxel plus gemcitabine in metastatic pancreatic adenocarcinoma: an observational study
    Servetto, Alberto
    Santaniello, Antonio
    Napolitano, Fabiana
    Foschini, Francesca
    Marciano, Roberta
    Cascetta, Priscilla
    Amato, Anna Rita
    Augurio, Maria Rosaria
    Maresca, Lucia
    De Placido, Pietro
    De Placido, Sabino
    Formisano, Luigi
    Bianco, Roberto
    FUTURE ONCOLOGY, 2022, 18 (21) : 2643 - 2654
  • [32] Weekly nab-paclitaxel (nab-P) plus gemcitabine (gem) or carboplatin (carbo) vs gem/carbo as first-line treatment for metastatic triple-negative breast cancer (mTNBC) in a phase 2/3 trial (tnAcity).
    Yardley, Denise A.
    Cortes, Javier
    Coleman, Robert E.
    Conte, Pier Franco
    Brufsky, Adam
    O'Shaughnessy, Joyce
    Wright, Gail Lynn Shaw
    Eakle, Janice F.
    Wilks, Sharon
    Shtivelband, Mikhail
    Young, Robyn R.
    Bengala, Carmelo
    Li, Huiling
    Miller, Julie Ann
    Barton, Debora
    Harbeck, Nadia
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [33] tnAcity: A phase II/III trial of weekly nab-paclitaxel (nab-P) plus gemcitabine (gem) or carboplatin (carbo) versus gem/carbo as first-line treatment for metastatic triple-negative breast cancer (mTNBC).
    Yardley, Denise A.
    Brufsky, Adam
    Coleman, Robert E.
    Conte, Pier Franco
    Cortes, Javier
    Glueck, Stefan
    Nabholtz, Jean-Marc A.
    O'Shaughnessy, Joyce
    Li, Li
    Barton, Debora
    Beck, Robert M.
    Harbeck, Nadia
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [34] Efficacy and safety of weekly nab-paclitaxel (nab-P) plus gemcitabine (Gem) in Chinese patients (Pts) with metastatic adenocarcinoma of the pancreas (MPC): A phase II study
    Yu, X.
    Shen, L.
    Hao, J.
    Wang, L.
    Pan, H.
    Han, G.
    Xu, J.
    Zhang, Y.
    Yang, S.
    Ying, J.
    Li, M.
    Begic, D.
    Lu, B.
    Xu, R.
    ANNALS OF ONCOLOGY, 2015, 26 : 66 - 67
  • [35] Second-line treatment of modified FOLFIRINOX or nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma
    Ozaka, Masato
    Sasaki, Takashi
    Yamada, Ikuhiro
    Kanata, Ryo
    Akiyama, Dai
    Katagiri, Tomoko
    Takano, Koichi
    Matsuyama, Masato
    Sasahira, Naoki
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
  • [36] APACT: Phase III randomized trial of adjuvant treatment with nab-paclitaxel (nab-P) plus gemcitabine (Gem) versus Gem alone in patients (pts) with resected pancreatic cancer (PC).
    Tempero, Margaret A.
    Cardin, Dana Backlund
    Goldstein, David
    O'Reilly, Eileen Mary
    Philip, Agop Philip
    Riess, Hanno
    Macarulla, Teresa
    Yung, Lotus
    Li, Mingyu
    Lu, Brian D.
    Biankin, Andrew
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
  • [37] APACT: a Phase III Trial of nab-Paclitaxel (nab-P) Plus Gemcitabine (Gem) vs Gem Alone as Adjuvant Therapy for Patients (pts) with Resected Pancreatic Cancer (PC)
    Tempero, M. A.
    Cardin, D.
    Biankin, A.
    Goldstein, D.
    Moore, M.
    O'Reilly, E. M.
    Philip, P.
    Riess, H.
    Macarulla, T.
    Yung, L.
    Wei, X.
    Lu, B.
    PANCREAS, 2014, 43 (08) : 1416 - 1416
  • [38] Gemcitabine (G) plus nab-paclitaxel (nab-P) plus chemoradiation (CRT) in locally advanced pancreatic cancer (LAPC)
    Olowokure, Olugbenga Olanrele
    Bedoya, Ivan Dario
    Mierzwa, Michelle Lynn
    Torregroza, Maria Patricia
    Dwivedi, Alok Kumar
    Wang, Jiang
    Smith, Milton T.
    Schmulewitz, Nathan
    Kucera, Stephen
    Choe, Kyuran Ann
    Ristagno, Ross
    Rudich, Steven
    Sussman, Jeffrey J.
    Ahmad, Syed A.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [39] International phase II trial of weekly nab-paclitaxel (nab-P) plus gemcitabine (Gem) in patients with locally advanced pancreatic cancer (LAPC): LAPACT
    Philip, P.
    Kayitalire, L.
    Nydam, T.
    Penenberg, D.
    Hammel, P.
    ANNALS OF ONCOLOGY, 2015, 26
  • [40] Phase IB trial of ADI-PEG 20 (A) plus nab-paclitaxel (nab-P) and gemcitabine (gem) in patients with advanced pancreatic cancer (PC)
    Lowery, Maeve Aine
    Harding, James J.
    Yu, Kenneth H.
    Kelsen, David Paul
    Bomalaski, John S.
    Glassman, Danielle C.
    Covington, Christina M.
    Brenner, Robin
    Hollywood, Ellen
    Barba, Adalberto
    Johnston, Amanda
    Liu, Kay Chia-Wei
    Capanu, Marinela
    Abou-Alfa, Ghassan K.
    O'Reilly, Eileen Mary
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)
12345